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Abstract 
Human serum albumin (HSA) nanoparticles are considered to be versatile carrier of anticancer 
agents in efficiently delivering the drug to the tumor site without causing any toxicity. The aim 
of the study was to develop stable HSA nanoparticles (NPs) of drug irinotecan (Iro) having 
slightly water solubility and moderate HSA binding. A novel strategy of employing a hydrophilic 
non-ionic surfactant polysorbate 80 which forms protein-polysorbate 80 complex with increased 
affinity and improvement in Iro-HSA binding has been used to maximize the loading and 
entrapment efficiency of Iro in HSA-NPs. Bespoke nanoparticles with entrapment efficiency 
(79.09%) and drug loading of 9.62% could be achieved with spherical shape and particle size of 
77.38 nm, 0.290 polydispersity index and -23.7 mv zeta potential. The drug entrapment in 
nanoparticles was confirmed by Differential Scanning Calorimeter, Fourier Transformation 
Infrared Spectroscopy and Fluorescence spectroscopy. In-vitro release of Iro from nanoparticles 
showed biphasic-release with initial burst followed by prolonged release upto 24h. The short-
term stability investigation of nanodispersion showed no significant changes in physicochemical 
properties of nanoparticles. Long-term studies on freeze-dried Iro-HSA-NPs indicated good 
stability of nanoparticles up to 12 months. This is the first report for efficient fabrication of Iro 
delivery system based on HSA nanoparticles. 
 
Keywords: Human serum albumin, nanoparticles, Irinotecan, polysorbate 80, desolvation, high 
pressure homogenization, response surface methodology, factorial design, stability studies 
 
 
 
 
 
 
 
 
 
  
1. Introduction 
Nanoparticles (NPs) are solid or liquid colloidal particles ranging in size from 10 to1000 nm and 
can be used as drug-carrier platforms (Singh and Lillard, 2009). The most recent development in 
designing drug delivery system has been focused upon the protein-based nanomedicine, due to 
their biocompatibility and biodegradability coupled with low toxicity (MaHam et al., 2009). 
Human serum albumin (HSA), a multifunctional protein for drug delivery has drawn 
considerable attention in pharmaceutical field in view of its non-toxic, non-immunogenic, 
biocompatible and biodegradable properties (Sleep, 2015). It also has multiple binding sites, 
which can act as a carrier for the various drugs. As compared to other NPs made from synthetic 
polymer, HSA NPs are well tolerated in vivo without any side effects, which is supported by the 
findings of several clinical studies on commercial HSA based NPs such as Albunex® (Barnhart 
et al., 1990) and Abraxane® (Green et al., 2006). In addition HSA can be preferentially taken up 
by tumor through well known gp60 pathway, making it an attractive carrier for the delivery of 
anticancer drugs (Kratz, 2008). Thus, HSA NPs represent a promising strategy for targeted 
delivery of anticancer drugs to tumor cells by enhancing the drug bioavailability and distribution, 
diminishing their toxicity and reducing the body's response towards drug resistance (Sheng et al., 
2014). 
Irinotecan (Iro) an anticancer agent, inhibits topoisomerase I involved in DNA replication (Fuchs 
et al., 2006) is the first line treatment of metastatic colorectal cancer (Douillard et al., 2000; 
Sobrero et al., 2008). But unfortunately, Camptosar® the commercial injection of Iro apart from 
causing irritation of vein and damage to tissues near to administration site causes various 
gastrointestinal side effects including severe nausea, vomiting and diarrhea. It also results in 
reduction in the number of white and red blood cells (Hardman et al., 1999). This creates the 
need to develop an alternative safer drug delivery system that can target the tumor site and 
overcome the side effects of the drug due to its non-specific distribution.Various drug delivery 
systems based on novel polymers are being developed for the safe delievery of the drug (De et 
al., 2009; Zhu et al., 2013) lipid (Waterhouse et al., 2014), magnetic (Tamyurek et al., 2015), 
PLGA (Valencia et al., 2013) and chitosan (Guo et al., 2013) carriers also have been investigated 
for nanoparticulate delivery of Iro. Recently, the US FDA (United States Food And Drug 
Administration) approved an Iro liposome injection,Onivyde® to treat patients with advanced 
metastatic pancreatic cancer (Passero Jr et al., 2016). However to best of our knowledge there is 
no report on Iro deliverysystem based on HSA NPs. 
HSA NPs can be prepared by various methods including desolvation (Weber et al., 2000), 
emulsification (Yadav and Vadali, 2008), thermal gelation (Yu et al., 2006), nanospray drying 
(Lee et al., 2011), nanoparticle albumin bound (NAB)-technology (Cortes and Saura, 2010) and 
self-assembly (Desai, 2007). Among all these methods, desolvation is most commonly used 
method because of high reproducibility and the production of NPs with more controlled drug 
release properties (Langer et al., 2003). Water-soluble drugs such as doxorubicin (Dreis et al., 
2007), ciprofloxacin (Kumar and Jain, 2007), imatinib (Kamali et al., 2015) and 5-fluorouracil 
(Maghsoudi et al., 2008) have been efficiently loaded in albumin NPs by desolvation technique. 
However, it is challenging to prepare HSA NPs with sufficient drug loading and entrapment 
efficiency, especially for drugs having limited solubility and poor drug binding. Iro being 
moderately water soluble (Ci et al., 2014) and average albumin binding affinity (30-60%) poses 
such obstacles (Combes et al., 2000). 
The present study reports a new strategy of employing a hydrophilic non-ionic surfactant 
polysorbate 80 during drug HSA incubation to maximize the loading and entrapment efficiency 
of Iro in HSA-NPs. Polysorbate 80, a approved safe non ionic surfactant was explored in order to 
prepare stable NPs with high loading of drug. When polysorbate 80 is added to aqueous solution 
of protein, surfactant-protein complexation occurs (Delgado-Magnero et al., 2014) leading to 
increased affinity for Iro and improvement in Iro-HSA binding. As Iro has slight water solubility 
(25mg/mL) and limited albumin binding affinity, it can be trapped inside clusters of polysorbate 
80 formed by binding to non-specific surface regions on albumin. This approach was used to 
improve the binding of Iro to HSA with enhanced drug entrapment and loading in NPs. To 
achieve tunable NPs, various factors affecting the process of preparation of HSA NPs and 
material attributes of the formulation were identified using Ishikawa diagram and ranked for 
probability of risk from low to high using risk estimation matrix (REM). The critical factors 
affecting the entrapment of drug were further optimized by 32 factorial design which is a widely 
used approach for optimizing systems that depend on factors (dos Santos et al., 2005). The 
resultant bespoke Iro-HSA-NPs has been extensively characterized by dynamic light scattering 
(DLS), field emission surface electron microscopy (FESEM), Fourier transformation infrared 
spectroscopy (FTIR), differential scanning calorimeter (DSC) and fluorescence spectroscopy. 
The entrapment efficiency, drug loading and in vitro release of drug from NPs were also 
determined. Industrial manufacturing and commercialization is often governed by the stability of 
the product. The developed NPs were therefore studied for short and long term stability over 
two-year period. 
Material and methods 
2.1. Material 
Irinotecan hydrochloride trihydrate was obtained as a gift sample from Khandelwal Laboratories 
Pvt.Ltd, Mumbai, India. Human Serum albumin (Alburel 20%) was purchased from Reliance 
Life Sciences, Mumbai, India. Polysorbate 80 and absolute ethanol was obtained from S.D Fine 
Chemicals Ltd., Mumbai, India. Trehalose and mannitol was gift sample from Signet, Mumbai, 
India. 
2.2. Fluorescence quenching Study 
Fluorescence spectroscopy is the most common technique used to study the interaction between 
drug and protein (Anand and Mukherjee, 2013). Fluorescence spectra were recorded with Perkin 
Elmer LS-55 fluorescence spectrometer,USA. Emission spectra were acquired with an excitation 
wavelength of 280 nm and emission range of 290–400nm. Both the excitation and emission slit 
widths were kept at 5nm each.The quenching experiment was carried out by adding 20-400µg of 
Iro in 1mL of HSA solution (0.1mg/mL) and fluorescence was measured in 1 cm path length 
quartz cuvette. Fluorescence intensities at 340 nm were recordedas a function of Iro 
concentration. Further, binding parameters were obtained using Stern–Volmer equation (Samant 
et al., 2014): 
𝐹𝐹0/𝐹𝐹 =  1 + 𝑘𝑘𝑘𝑘 ·  𝜏𝜏0 . [𝑄𝑄 ] =  1 +  𝐾𝐾𝑠𝑠𝑠𝑠[𝑄𝑄]    ……………………(1) 
where, F0 and F are fluorescence intensities of HSA in the absence and presence of Iro, 
respectively, Ksv is the Stern-Volmer quenching constant, [Q] is the concentration of Iro, kq is 
the bimolecular quenching constant, and τ0 is the lifetime of the fluorophore. 
In another experiment, to understand the individual effect of polysorbate 80 and Iro on 
fluorescence at the equivalent concentrations used during the preparation of HSA NPs, HSA 
solution was added with polysorbate 80 (50 fold molar excess) and Iro (0.25µM).  Fluorescence 
emission spectrum was recorded from 280nm-500nm following excitation at 280nm with the slit 
width of 5 nm. Moreover, spectrum was also recorded when both polysorbate 80 and Iro were 
added simultaneously to HSA. 
2.3. Preparation of human serum albumin nanoparticles of irinotecan (Iro-HSA-NPs) 
Iro-HSA-NPs were prepared by desolvation technique according to the method described by 
Weber et al (Weber et al., 2000) with some significant modifications. For a 100 mL batch, 15 
mL of 20% w/v HSA in double distilled water was added to polysorbate 80 (3%w/v) followed by 
incubation with 100 mg of Iro for 3 hours. After incubation, the resultant solution was desolvated 
by ethanol at the addition rate of 1mL/min under stirring at constant speed of 500 rpm till the 
turbidity appeared. After desolvation, ethanol was evaporated and NPs were cross-linked by 
heating at 600C and homogenized in a high-pressure homogenizer (GEA NiroSoavi, Panda Plus, 
Italy) with attached water circulation pump (Lab Companion, Biotechnical services, USA) to 
maintain the temperature. For comparison NPs were also prepared using normal desolvation 
technique without polysorbate 80 and incubation prior to the addition of ethanol. 
2.4. Factors affecting quality of nanoparticles 
A variety of product and process parameters were identified using the Ishikawa’s diagram to 
delineate potential cause and effect relationship on the critical quality attributes (CQAs) of Iro-
HSA-NPs (Fig.S1). CQAs influencing the product performance were selected as particle size, 
polydispersity index (PDI), drug loading (DL) and entrapment efficiency (EE). Further risk 
estimation matrix (REM) (Table S 1) helped with qualitative analysis of low, medium and high 
risk related toproduct parameters and process parameters influencing the CQAs of Iro-HSA-NPs. 
The parameters at high risk have an increased probability of affecting the CQAs and were further 
identified and analyzed. 
Some of the factors such as the choice of desolvating agent,its addition rate, stirring speed were 
determined according to the literature and confirmed with initial screening (Maghsoudi et al., 
2008). Incubation time and concentration of polysorbate 80 were defined and optimized prior to 
desolvation. The other factors such as ethanol concentration and homogenization pressure were 
also optimized. Iro:HSA ratio and crosslinking temperature considered as the most critical 
factors affecting entrapment efficiency and drug loading remained undefined. These two factors 
vary with the type and amount of drug, so required cooperative optimization to get maximum 
entrapment and loading of Iro.  
2.5. Design of experiment by 32 factorial design  
The two most influential factors Iro:HSA ratio and the crosslinking temperature were optimised 
using 32 factorial design (Design Expert® 10 software) keeping the other factors constant.HSA 
concentration was varied from 10 to 30 mg/mL with Iro concentration at 1mg/mL giving Iro: 
HSA ratio (X1) of 1:10, 1:20 and 1:30. Whereas, homogenization crosslinking temperatures (X2) 
selected were 50, 55 and 600C. These two input factors were coded as X1 and X2 with their levels 
coded -1, 0 and +1. Particle size (Y1),  PDI (Y2),  % EE (Y3), and %DL (Y4) were considered as 
the response variables. 
2.6. Freeze drying of Iro-HSA-NPs 
Iro-HSA-NPs were freeze dried in Epsilon 2- 4 LSC freeze dryer (Martin Christ, Germany) with 
30 hour cycle including primary drying at the shelf temperature of -500C for 5 hours followed by 
an increase in temperature to -250C at the pressure of 0.10 mbar for 20 hours. Secondary drying 
was carried out by increasing the temperature up to 250C at 0.01 mbar for next 5 hours (Anhorn 
et al., 2008). Trehalose and mannitol were investigated as cryoprotectant to inhibit the particle 
growth during lyophilization. 
2.7. Characterization of Iro-HSA-NPs 
2.7.1 Particle size and Polydispersity Index (PDI) 
For the determination of particle size and PDI, samples were diluted with double distilled water 
in polystyrene cuvettes and measured at a temperature of 25°C and a scattering angle of 90° by 
dynamic light scattering (DLS) using Beckman coulter N5 Particle size analyzer (Beckman, 
USA). PDI was also measured to characterize the size distribution. The results are reported as the  
average of three values. 
2.7.2 Zeta potentialMeasurement 
Zeta Potential of the particles was determined using Zetasizer (Malvern instrument Ltd, UK) at 
25°C after making suitable dilution with de-ionized double distilled water. 
2.7.3 Entrapment Efficiency (% EE) 
To assess the drug entrapment in Iro-HSA-NPs, 1 mL of sample was centrifuged at 60,000 rpm 
for 120 minutes using Beckman coulter optima MAX-XP ultracentrifuge (Beckman, USA). 
Supernatant was analyzed for the Iro and entrapment efficiency was calculated using following 
equation: 
 
2.7.4 Drug loading (%DL) 
Accurately weighed amount of the NPs were added to 1 mL of phosphate buffer saline (pH 7.4). 
The particles in the solution were degraded by adding trypsin (0.1 mg/mg of NPs) (Dubey et al., 
2015). The mixture was stirred overnight, centrifuged and the supernatant was analyzed for drug 
content. Drug loading was calculated by the following formula: 
 %𝑬𝑬𝑬𝑬 = (𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑇𝑇𝑎𝑎𝑇𝑇𝑎𝑎𝑎𝑎𝑇𝑇 𝑇𝑇𝑜𝑜 𝐼𝐼𝐼𝐼𝑇𝑇 𝑇𝑇𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝐴𝐴𝑎𝑎𝑇𝑇𝑎𝑎𝑎𝑎𝑇𝑇 𝑇𝑇𝑜𝑜 𝐼𝐼𝐼𝐼𝑇𝑇 𝑖𝑖𝑎𝑎 𝑆𝑆𝑎𝑎𝑆𝑆𝑎𝑎𝐼𝐼𝑎𝑎𝑇𝑇𝑇𝑇𝑇𝑇𝑎𝑎𝑇𝑇) 𝑋𝑋 100
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐼𝐼𝐼𝐼𝑇𝑇 𝑇𝑇𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎  … 2  
 %𝑫𝑫𝑫𝑫 = 𝐴𝐴𝑎𝑎𝑇𝑇𝑎𝑎𝑎𝑎𝑇𝑇 𝑇𝑇𝑜𝑜 𝐼𝐼𝐼𝐼𝑇𝑇 𝑖𝑖𝑎𝑎 𝑁𝑁𝑁𝑁𝑠𝑠  𝑋𝑋 100
𝑊𝑊𝑎𝑎𝑖𝑖𝑊𝑊ℎ𝑇𝑇 𝑇𝑇𝑜𝑜 𝑁𝑁𝑁𝑁𝑠𝑠  ………3  
 2.7.5 Field Emission Gun Surface Electron Microscopy (FEG-SEM) 
Surface morphology of both lyophilized Iro-HSA-NPs and Iro-HSA-NPs after reconstitution of 
lyophilized powder was studied. Samples were prepared by overnight drying on aluminum foil 
and were transferred to the copper grid and examined under FEG-SEM (JSM-7600F, JEOL, 
USA) using accelerating voltage of 5kv and magnification up to 40,000X.  
2.7.6 Differential Scanning Calorimetry (DSC) 
DSC of Iro, HSA and lyophilized Iro-HSA-NPs were performed on a Mettler DSC 823 (Mettler 
Toledo, Switzerland). The powdered samples were weighed, put into an aluminum pan, and 
sealed carefully. During measurement, the sample and reference cell were purged with nitrogen 
gas. The samples were placed in the sample cell and were heated up to 3000C by increasing the 
temperature at a rate of 100C/minute and thermograms were recorded. 
2.7.7 Fourier Transform Infrared (FTIR) Spectroscopy 
Infrared spectra were recorded with FTIR spectrometer to study the conformational changes in 
NPs. FTIR is a prevailing means of identifying types of chemical bonds in a molecule by 
producing an infrared absorption spectrum. Samples were prepared by KBr pellet method. The 
sample (0.5 to 1.0 mg) was thoroughly mixed with approximately 100 mg of dry KBr powder. 
Spectra were scanned from 4000-400 cm-1. 
2.7.8 Fluorescence Spectroscopy 
The fluorescence spectra of blank HSA NPs and Iro-HSA-NPs were measured after excitation at 
280 nm, scanned at an emission wavelength range between 290–400nm at room temperature 
using Perkin Elmer LS-55 fluorescence spectrometer, USA. 
2.7.9 In vitro drug release study 
To study the release of Iro from Iro-HSA-NP, NPs equivalent to 1mg of Iro were enclosed within 
dialysis bags (dialyzing membrane-150, molecular weight cut off 12000-14000 Dalton). The 
dialyzing membrane was soaked for 30 minutes in water prior to use. The dialysis bag was kept 
in 1000 mL of phosphate buffer saline pH 7.4 or phosphate buffer pH 5 and maintained at 37°C 
± 1°Cup to 24 hours with continuous stirring at 500 rpm (Nastase et al., 2014). After fixed time 
intervals, 2 mL of sample volume were withdrawn and replenished with the fresh buffer to 
maintain the sink condition. The amount of Iro released in dissolution media was quantified by 
HPLC. 
2.8 Quantification of Iro by HPLC 
HPLC was performed on column BDS Hypersil C 18 (250 × 4.6 mm internal diameter, pore size 
5 μm; Thermo scientific, USA) with the column temperature of 400C using Agilent 1200 HPLC 
(Agilent Technologies, USA). The mobile phase used was water: acetonitrile (60:40), pH 
adjusted to 3 with orthophosphoric acid at the fixed flow rate of 0.8ml/min. Iro was detected at 
225 nm by PDA detector (Poujol et al., 2003). The amount of Iro in the samples was quantified 
using calibration curve plotted with known Iro concentrations. 
2.9 Short term and long term stability studies 
Short-term stability of fresh Iro-HSA-NP dispersions was determined by storing them at 40 and 
250C respectively. Samples were withdrawn after 1, 24, 48, 72 and 96 hours and were analyzed 
for particle size, PDI and zeta potential. For long-term stability studies, lyophilized Iro-HSA-NPs 
were stored and packed in sealed glass vials at 40C. The samples were withdrawn at 1, 3, 6, 12 
and 24 months and were evaluated for any significant changes in the particle size, PDI, zeta 
potential and entrapment efficiency. 
2.10 Statistical analysis 
The relationships between responses and variables of all models were derived by DX-10 (Design 
Expert® 10). The suitability of quadratic models was conﬁrmed by values of R2and one-way 
analysis of variance (ANOVA). All other experiments were performed in triplicates and data was 
analyzed by one-way ANOVA with post Bonferroni’s test. Differences with p-value<0.05 (*) 
were considered significant. 
3 Result and discussion 
3.1 Fluorescence Quenching 
HSA shows a strong fluorescence emission with a peak at 340 nm on excitation at 280 nm due to 
its single tryptophan residue (Trp-214) (Trynda-Lemiesz, 2004). The fluorescence of protein is 
quenched by the addition of drug which binds to the tryptophan residues (Reichenwallner and 
Hinderberger, 2013). On addition of different concentrations of Iro to a fixed concentration of 
HSA solution, proportional decrease in the fluorescence intensity of HSA was observed 
indicating interaction between HSA and Iro was concentration dependent (Supplementary Fig.S2 
a). A blue shift of maximum emission wavelength revealed an increase of hydrophobic amino 
acid residues formed by the interaction between Iro and HSA (Chen et al., 2016). The micro 
environmental polarity around the tryptophan residues converted from hydrohilicity to 
hydrophobicity, folding the peptide chain to form new conformation (Mahesha et al., 2006). 
Furthermore, the appearance of an isosbestic point in the fluorescence spectra clearly indicated 
that there was a simple equilibrium between the free HSA and bound one (Sun et al., 2012b). 
The plot of F0/F versus [Q] showed a linear curve and the slope corresponds to the Ksv value 
(Supplementary Fig. S2b). The Stern-Volmer plots were linear over the whole concentration 
range studied and yielded typical Ksv-value of 0.002 X 103 mL.µg-1. Binding constant calculated 
by plotting log [F0 − F /F] versus log [Q] (Supplementary Fig. S2c) was found to be 3.14 mM-1. 
Both the Ksv and K revealed that the interaction of Iro with HSA was weak; much lower than 
other drugs e.g. lapatinib, 5-fluorouracil and captopril (Gao et al., 2011; Kabir et al., 2016; Sun 
et al., 2012a). Verily, this also is in consonance with an earlier study, which has reported other 
proteins to have interacted more with Iro than HSA in a magnetic nanoparticle system 
(Tamyurek et al., 2015).  
The quenching experiments carried out by the addition of Iro and polysorbate 80 separately or 
together to HSA solution showed quenching of the HSA fluorescence (Fig. 1). Quenching in the 
fluorescence indicated modification of the microenvironment and conformational changes in 
HSA molecules due to interaction with the added molecules (Zhang et al., 2008). Among these 
spectrums, Iro was found to have very low quenching and weak interaction. The results are 
supported by our earlier experiment elucidating the poor binding constant of Iro-HSA. The 
quenching exhibited by polysorbate 80 was found to be higher than the Iro and can be described 
by the strong interaction of polysorbate 80 and HSA to form polysorbate80-HSA complex 
(Delgado-Magnero et al., 2014). A significantly higher quenching was observed on addition of 
both Iro and polysorbate 80 to the HSA solution. This could be possibly due to modification of 
the HSA structure with formation of polysorbate80-HSA complex (Delgado-Magnero et al., 
2014), resulting in the increased affinity and improvement in Iro-HSA binding. Change in 
affinity of drugs to HSA in presence of third compound has been previously reported (Shiri et al., 
2017). This approach was further exploited to enhance the encapsulation of Iro in HSA-NPs.  
3.2 Risk assessment studies 
The CQAs earmarked for Iro-HSA-NPs included particle size, PDI, entrapment efficiency and 
drug loading. Selection criterion of the CQAs was based upon the prior literature, knowledge and 
experience on the formulations of HSA NPs. Following the identification of the parameters 
affecting CQAs; they were ranked according to their criticality in terms of risk. REM was 
constructed in order to analyze the risk(s) associated with each material attribute and process 
parameters. The qualitative analysis of each product and process parameter was carried out by 
ranking them as low, medium and high levels representing the probability of risk and severity of 
the related effect as presented in Table S1. Based on the REM, the high to medium risk variables 
were optimized and their effect on CQAs was investigated. 
3.3 Preparation of Iro-HSA-NPs 
Polysorbate 80 is the most common non-ionic surfactant used in the formulation of various 
therapeutic products as a solubility enhancer and stabilizing agent (Kerwin, 2008). The addition 
of polysorbate 80 to HSA can stabilize the protein molecules by directly binding to the 
hydrophobic surface areas of protein minimizing protein-protein interaction and thus aggregation 
(Garidel et al., 2009). Secondly, it interacts with the proteins in order to create protein-
polysorbate 80 complex and making protein more hydrophilic as compared to native protein 
(Delgado-Magnero et al., 2014). It has been previously reported that interaction between albumin 
and polysorbate 80 is not solely driven by the hydrophobic interaction between the surfactant 
tails and the apolar amino acids of the protein, but there is also a significant contribution from 
the interactions through the polar heads. The surfactant interacts with the protein predominantly 
via the polyoxyethylene groups of their polar heads through hydrogen bonds and van der Waals 
interactions. In addition, polysorbate 80 binds to non-specific surface regions on albumin, self-
assembling in clusters over the protein surface as micelles through cooperative hydrophobic 
interactions with other surfactant molecules in solution, thus increasing the solubility of the 
surfactant: protein complex (Zadymova et al., 2006). These properties of polysorbate 80 were 
exploited to prepare the stable HSA NPs of Iro with enhanced drug entrapment and loading. Fig. 
2 shows the schematic representation of development of Iro loaded HSA-NPs. For the 
preparation of Iro-HSA-NPs, polysorbate 80 was added to HSA in order to form the 
polysorbate80-HSA complexes. Further prolonged incubation with the Iro allowed drug to entrap 
in the self-assembled clusters of polysorbate 80 over the protein surface. Therefore, 3% w/v of 
polysorbate 80 (50 fold molar excess than HSA) was added to ensure the complete 
polysorbate80-HSA interaction and complex formation followed by sufficient incubation time of 
3h (Table S2) for drug molecules to be incorporated within the polysorbate 80 micelles 
(Zadymova et al., 2006). Moreover, polysorbate 80 is well tolerated as excipient for intravenous 
injection (lyophilized powder) up to 12% according to FDA guidelines on inactive ingredients. 
Desolvation with ethanol reduced the solubility of HSA in aqueous phase and resulted into the 
formation of Iro-HSA-NPs. However, precipitation of drug was observed when attempt was 
made to prepare the NPs by desolvation without presence of polysorbate 80 incubation clearly 
indicating the important role of polysorbate 80 in loading of Iro. 
 
After desolvation, cross-linking by glutaraldehyde is generally used to harden the albumin NPs 
(Elzoghby et al., 2012). Glutaraldehyde has been reported to reduce the number of amino groups 
on the surface of HSA NPs and also decrease the stability of the carrier system. In addition 
glutaraldehyde as chemical cross linker also has various kind of toxicity (Zeiger et al., 2005). In 
our method we combined thermal crosslinking with high-pressure homogenization, that protects 
the native HSA, avoids denaturation and results in high entrapment and loading of the drug 
(Desai and Soon-Shiong, 2004; Desai et al., 1999). Moreover, applying high pressure by passing 
through high pressure homogenizer reduced the particle size to nanoscale and increased the 
stability of NPs (Kamiya et al., 2009). 
3.3 Factors affecting the quality attributes of Iro-HSA-NPs 
3.3.1 Polysorbate 80 concentration 
Increase in the concentration of polysorbate 80 (1-3% w/v) led to decrease in mean particle size 
and PDI of the NPs (Fig. 3a). This was found to be in good agreement with our previous report 
(Sidhaye et al., 2016). Polysorbate 80 was also found to have profound effect on entrapment 
efficiency and drug loading (Fig. 3b) with maximum being achieved at 3% w/v polysorbate 80 
concentration. Much higher concentration of polysorbate 80 than its critical micelle 
concentration (CMC) in pure water (15mg/L) was required, as CMC of polysorbate 80 is known 
to increase in the presence of albumins because of protein surfactant interaction (Ruiz-Pe˜naa et 
al., 2010). Furthermore the self-assembled surfactant clusters of polysorbate 80 over the protein 
surface enabled higher encapsulation of drug.  
3.3.2 Ethanol concentration 
Addition of ethanol to the albumin cause phase separation of albumin due to its diminished water 
solubility forming NPs (Langer et al., 2003). Ethanol concentration has been reported to play an 
influential role in determining the particle size of HSA NPs. Larger aggregates were generated 
during the initial desolvation at lower concentration of ethanol due to the exposure and 
interaction of hydrophobic chains in protein molecules resulting into the aggregation (Li et al., 
2007). A gradual decrease in the particle size and PDI of Iro-HSA-NPs was observed when 
concentration of ethanol was increased from 50 to 80% v/v (Fig. 3c) not only making the 
particles with lower particle size but with more uniform distribution. The plausible reason for the 
decrease in the particle size was the breakdown of larger aggregates formed during the initial 
desolvation into smaller particles with uniform size. This is in conformance with previous 
literature reports describing decrease in particle size of NPs with increase in percentage of 
ethanol (Ghosh et al., 2016; Teng et al., 2012). 
3.3.3 Homogenization cycles and pressure 
High-pressure homogenization is industrially feasible and scalable process to fabricate the NPs 
(Desai et al., 2004). NPs prepared at lower homogenization pressure of 200 bars for 8 cycles 
resulted in the reduction of mean particle size to 302 nm. Escalating pressure to 400 bars (8 
cycles) and further to 600 bars (8 cycles) reduced the mean particle size to 78 nm. However, 
further increase in the pressure to 800 bars did not cause any reduction in particle size and PDI 
but lead to aggregation of particles (Table 1). Once maximal disintegration of particles has been 
achieved, additional energy put into the system cannot be used for further size reduction of NPs. 
The energy put in can only expedite the velocity of the particles, giving them sufficient kinetic 
energy to circumvent the stabilization resulting in coalescence and increase in mean size 
(Shegokar et al., 2011). Therefore in this context, homogenization pressure was optimized to 600 
bars with 8 cycles to get the smallest NPs size of 78 nm. Previously Zu et al has produced BSA 
NPs of size 144 nm after seven optimized cycles at the pressure of 800 bars (Zu et al., 2013). 
3.3.4 Iro: HSA Ratio 
No apparent change in the particle size of NPs was discerned when Iro: HSA ratio was increased 
from 1:10-1:30 (Fig. 3d). This is similar to observations by Langer et al (Langer et al., 2003). 
But at Iro HSA ratio of 1:40, abrupt increase in the particle size was visible. This may plausibly 
be due to high concentration of protein resulting in viscous solution which caused slower 
nucleation rates leading to larger particles (Galisteo-González and Molina-Bolívar, 2014; Joye 
and McClements, 2013). Consequently, high super saturation also speeds up agglomeration 
through greater incidence of particle collision eventuating larger NPs (Kakran et al., 2012). 
Entrapment efficiency and drug loading of Iro evidently increased with increase in HSA 
concentration with maximum being achieved at 1: 30 ratio (Fig. 3e). Higher amounts of HSA 
effected higher desolvation of the protein substantiating higher encapsulation of drug in the NPs. 
Further increase in HSA content did not contrive higher entrapment efficiency with 
consequential decline in percentage of drug loading (Li et al., 2008). 
3.3.5 Crosslinking temperature 
The thermal cross-linking mechanism has been shown to represent condensation between 
carboxylic groups and amino groups of adjacent protein chains (Esposito et al., 1996). It was 
observed that cross-linking temperature had a positive effect on entrapment efficiency and drug 
loading in Iro-HSA-NPs (Asghar et al., 2014). The entrapment and loading of Iro in HSA NPs 
was enhanced with increase in crosslinking temperature from 500 to 600 C (Fig. 3f). Maximum 
entrapment and drug loading was achieved when NPs were cross-linked at 600C. However, 
further increase in the temperature (>600C) lead to the formation of gel (Murata et al., 1993). The 
temperature during the whole homogenization process was maintained at 600 C to obtain higher 
degree of cross-linking and minimize re-dissolution of NPs in water (Chen et al., 1994). This 
also ensured high encapsulation of drug. The homogenizer temperature was gradually decreased 
from 600 to 300 C during removal of Iro-HSA-NPs from homogenizer to avoid aggregation of the 
NPs due to sudden temperature change.   
3.4 Response surface methodology and construction of model Equation 
In a 32 factorial design Iro: HSA ratio (X1) and crosslinking temperature (X2) at 3 levels were 
considered as two independent input variables while particle size, polydispersity index (PDI), % 
entrapment efficiency (%EE), % drug loading (%DL), were considered as response variables 
(Table 2). The data was analyzed by quadratic model in Design Expert software 10 and results of 
analysis of variance (ANOVA) are listed in Table 3. 
The ANOVA of the regression models demonstrates that the models are highly significant as 
evident from the high F values (F model for particle size = 31.22, F model for PDI= 5.79, F 
model for %EE= 335.43 and F model of % DL=31.39). Further, the correlation coefficient (R2) 
of 0.9750 (particle size), 0.7433 (PDI), 0.9963 (%EE) and 0.8997 (%DL) presents the goodness 
of fit of these models. It can be seen from predicted versus actual plot (Fig.S3) that the 
experimentally measured values are well in line with the predicted values. In all above stated 
models, the predicted R2 was found to be in reasonable agreement with the adjusted R2 i.e. the 
difference was less than 0.2. Furthermore, adequate precision measures the signal to noise ratio. 
A ratio greater than 4 is desirable. The ratio of 16.105 (particle size), 7.207 (PDI), 58.95 (%EE) 
and 14.79 (%DL) indicates an adequate signal and models can be used to navigate the design 
space. In ANOVA, the p value < 0.05 indicates the significance of model terms. With 
consideration of p values, the significant terms in particle size were crosslinking temperature 
(X2), interaction of Iro: HSA ratio and crosslinking temperature (X1X2), with quadratic effect of 
both factors (X12, X22). However, Iro: HSA ratio (X1) in the described range did not affect the 
particle size. For PDI, according to p values, crosslinking temperature (X2) and quadratic effect 
of Iro: HSA ratio (X12) were the significant model terms, whereas, no effect of Iro: HSA ratio 
(X1) and interaction of both factors (X1X2) were observed on PDI. While, the significant factors 
affecting entrapment efficiency were both Iro: HSA ratio (X1) and crosslinking temperature 
(X2). Though, no significant interaction and quadratic effects of these two factors were observed. 
Similarly, the most significant factors affecting drug loading was Iro: HSA ratio. But, there were 
no effect of crosslinking temperature, interaction and quadratic effects observed. The polynomial 
equations for the estimation of particle size, PDI, entrapment efficiency and drug loading are as 
follow: 
 Particle Size  = +71.55 + 0.09X1 + 1.33X2 - 2.28X1X2+ 3.22X12+ 6.66X22 ……. (4) PDI = +0.19 + 0.045X1+ 0.071X2 - 0.031 + 0.15X12 - 0.065X22 …….. (5) 
% EE = +60.27 + 9.96X1+ 7.43X2- 0.86X1X2+ 1.37X12+ 0.56X22 …………(6) 
% DL = +5.78 + 2.79X1+ 0.87X2+ 0.009X1X2- 0.36X12+ 0.95X22  …………… (7) 
The visual representation of the effect of factors on four CQAs in the form of 3 D response 
surface plots is given in Fig. 4. As seen from surface response plot (Fig. 4a), crosslinking 
temperature has positive effect on particle size. Particle size was found to increase with increase 
in crosslinking temperature whereas increase in Iro: HSA ratio did not show any significant rise 
in particle size. Similar effect was observed on PDI (Fig. 4b). PDI increased with increase in 
crosslinking temperature but was not affected by change in Iro: HSA ratio. It was observed that 
percent EE was greatly affected by change in both Iro: HSA ratio and crosslinking temperature 
and maximum %EE was achieved at their highest levels (Fig 4c). Increase in Iro: HSA ratio 
significantly increased the %DL, where as crosslinking temperature did not have any effect  (Fig. 
4d). 
To understand the tunability of Iro-HSA-NPs, design space was established by overlaying the 
contour plots for all four-response variables. As shown in Fig. 5a the design space (yellow 
region) observed was quite broad in the overlay plot for tailored Iro-HSA-NPs (particle size 
<80nm, PDI <0.4, %EE >70 and %DL >7). To understand the effect of individual response on 
design space, one response was changed at a time, while other three responses were kept 
constant. Design space varied according to the tailored responses, which in turn were dependent 
upon the input factors. If the particle size of NPs was tailored to be below 75nm instead of 80nm, 
the design space got significantly narrower (Fig. 5b). Tailoring of PDI from 0.4 to <0.3 (Fig 5c) 
entrapment efficiency >70 to >75% (Fig. 5d) also reduced the design space. However, altering % 
DL up to 8% did not show much effect on the design space (Fig. 5e). A final overlay plot was 
constructed to obtain the bespoke Iro-HSA-NPs (particle size <80nm, PDI <0.4, %EE >75% and 
%DL >9) (Fig. 5f), to meet our target profile of developing the NPs with low particle size and 
PDI with high drug entrapment and loading. 
3.5 Freeze Drying of Iro-HSA-NPs 
Lyophilisation is one of the most employed techniques to generate NPs with improved stability 
(Abdelwahed et al., 2006). Freezing generally creates many destabilizing stresses for NPs. 
Generation of ice crystals can mechanically damage NPs apart from augmented interaction due 
to increased nanoparticle concentration entailing aggregation or fusion (Dadparvar et al., 2014). 
After lyophilisation, Iro-HSA-NPs were reconstituted with water and were observed for any 
change in appearance and growth in the particle size (Table 4). Trehalose at 4% w/v 
concentration was found to be acceptable as cryoprotectant as it resulted in free flowing stable 
product which could be easily reconstituted to yield a translucent dispersion. The reconstituted 
dispersion did not show any significant change in particle size or PDI from the one prior to 
freeze-drying (Table 4). Trehalose is known to impart satisfactory protection from lyophilization 
of HSA protein, providing stability in the solid state (Han et al., 2007). Trehalose also preserves 
the HSA NPs during freeze-drying as it forms amorphous glass, which interacts with amorphous 
protein in the freeze-dried cake (Chang et al., 2005). Additionally, physical isolation of adjacent 
NPs because of presence of glassy cryoprotectant, reduce the freeze-concentration stress on NPs 
(Niu and Panyam, 2017). Trehalose containing formulations were superior to mannitol with 
better size conservation, exhibiting minimal increases in nanoparticle size and PDI following the 
freeze-drying procedure (Wilson et al., 2012). 
3.6 Physiochemical Characterization of NPs 
3.6.1 Particle Size, polydispersity index and zeta Potential 
Particle size and size distribution are important factor of NPs system that influence the drug 
release and stability of drug-loaded NPs (Singh and Lillard, 2009). Iro-HSA-NPs were found to 
have mean particle size of 77.38 nm with PDI of 0.290 (Fig. S4a). HSA a negatively-charged 
molecule (Langer et al., 2003), when desolvated  leads to the formation of intermolecular 
disulphide bonds that leads to protein aggregation and thus development of  NPs with negative 
charge (Jun et al., 2011). Surface charge also plays an important role in the stability of colloidal 
particles. Higher charge on NPs leads to the repulsion between particles and thus prevents 
aggregation (Honary and Zahir, 2013). Iro-HSA-NPs showed zeta potential of -23.50mv (Fig. 
S4b) which is sufficient to inhibit the particle agglomeration, thus increase the stability 
(Bhattacharjee, 2016). 
 3.6.2 Entrapment efficiency and drug loading 
High drug loading capacity is prudent for any drug carrier to curtail the amount of solid materials 
required per mL during injection. The entrapment efficiency and drug loading depends on factors 
such as the nature of the NPs material, encapsulating drug molecules, medium of nanoparticles 
fabrication and the type of drug loading method (Merodio et al., 2001). For albumin NPs it 
further counts on degree of binding between the drug and albumin molecule, leakage of drug and 
drug diffusion to the dispersed phase (Shen et al., 2008). The entrapment efficiency and drug 
loading maximized by optimized processes was 79.09% ± 4.37% and 9.62% ± 2.12% 
respectively. 
3.6.3 Field emission gun surface electron microscopy (FESEM) 
Surface examination of Iro-HSA-NPs by FESEM confirmed their spherical shape and smooth 
surface (Fig. 6a). The NPs were found to be present in aggregated form with particle size less 
than 100nm. The aggregation of NPs observed was due to loss of water content and powdered 
freeze-dried sample. Surface morphology of NPs was again examined after reconstitution of 
lyophilized NPs with water for injection, which showed both individual round and aggregated 
NPs with particle size within 100nm (Fig. 6b). These images further confirmed redispersibility of 
Iro-HSA-NPs on reconstitution, with trehalose maintaining stability during freeze-drying. 
3.6.4 Differential scanning calorimeter (DSC) 
The DSC thermogram of pure Iro exhibited an endothermic peak at 213°C corresponding to its 
melting point (Fig. 6c). An endothermic peak of HSA was observed at 100°C, where as Iro-
HSA-NPs exhibited no characteristics melting endotherm of drug indicating there was no 
crystalline drug present in the NPs (Venkateswarlu and Manjunath, 2004). The drug was present 
in the amorphous phase and was entrapped in NPs (Sun et al., 2015). This is in affirmation with 
previous literature reports (Dubey et al., 2015; Wei et al., 2014). 
3.6.5 Fourier transmission infrared spectroscopy (FTIR)  
FTIR spectroscopy is a useful technique for determining conformational and structural dynamics 
of proteins. Amide I band arise due to C=O stretching which ranges from1600 to 1700 cm-
1.Amide II band is due to the CH stretching and NH bending mode at ≈ 1548cm-1. Amide III 
band arise due to CN stretching and NH bending at around 1300 cm-1. Amide I band is 
considered to be more sensitive than amide II for studying the changes in the structural 
conformations of the HSA (Sekar et al., 2015). Fig.6d shows the FTIR spectra of HSA, Iro and 
Iro-HSA-NPs respectively. FTIR spectra of HSA showed the amide A peak at 3464 cm-1which 
got shifted to 3306 cm-1in Iro-HSA-NPs. Peak corresponding to CH stretching showed change 
from 2958 to 2924cm-1. Intensity of peaks corresponding to amide II band and I at 1661 cm-1 and 
1541cm-1were significantly reduced in HSA NPs. There was an alteration observed in the peaks 
of amide III band from 1305 cm-1to 1298 cm-1. The modifications observed inIro-HSA-NPs 
peaks recommend conformational changes in HSA molecule due to adsorption and entrapment of 
drug and formation of NPs. This is in good agreement with an earlier report (Rajith and 
Ravindran, 2014). 
3.6.6 Fluorescence Study 
Upon excitation at 280nm, quenching in the fluorescence emission of Iro loaded HSA NPs was 
observed against blank HSA NPs (Fig. 6e). Decrease in the fluorescence intensity with Iro-HSA-
NPs could be plausible ascribable to change in microenvironment of tryptophan residue 
responsible for producing fluorescence, suggesting conformational changes in HSA due to 
interaction of Iro, polysorbate 80 and HSA in NPs (Gong et al., 2015; Rohiwal et al., 2015). 
In vitro drug release 
Iro-HSA-NPs showed biphasic drug release, displaying initial burst release (20-25%) of drug in 
first thirty minutes of dissolution followed by the sustained release up to 24 hours (Fig 6f). This 
burst release can be credited to the weakly bound drug on the surface of NPs in polysorbate 80 
clusters. Later, the entrapped Iro released from the core of the NPs in a sustained manner due to 
the diffusion of drug across the albumin matrix, would give the opportunity of continual drug 
effect. 
3.7 Short term stability studies 
For short-term stability studies Iro-HSA-NPs aqueous dispersions prepared under optimized 
conditions were kept at 40C and 250 C for 96 hours. There was no significant change observed in 
particle size and zeta potential of NPs stored at 40C as well 250C, though the nanodispersions 
became more polydisperse as evidenced by higher PDI values (Fig.7). HSA nanodispersions 
have shown acceptable stability in previous reports (Dreis et al., 2007).  
3.8 Long-term stability studies 
Lyophilization, or freeze-drying, is widely used in the pharmaceutical industry to boost the long-
stability and increase the shelf life of many drug products by removing the total water content 
from the drug formulation apart from providing convenience of shipping in dry powder form. 
The long-term stability study revealed no significant increase in the particle size of Iro-HSA-NPs 
up to 12 months and was within the desired particle size of 100nm. A uniform particle size 
distribution was maintained as testified by the PDI of NPs. Previous reports demonstrate that 
HSA NPs can be stabilized for long-term storage after freeze drying when using adequate 
concentrations of suitable excipients (Anhorn et al., 2008). A significant increase (p value <0.05) 
in the particle size was observed after 24 months of storage along with increase in value of PDI 
(Fig. 8a and b). A decreased stability of Iro-HSA-NPs at the end of 24 months storage was 
further evidenced by lowered value of zeta potential which could ostensibly lead to 
agglomeration of NPs (Fig. 8c). Particle growth had no effect on entrapped drug as entrapment 
efficiency remained within acceptable limits even after 24 months (Fig. 8d). 
4 Conclusion 
In the present study, we have successfully prepared HSA NPs of a slightly soluble drug Iro 
having average albumin binding affinity by modified desolvation technique. Addition of 
polysorbate 80 into HSA solution resulted into polysorbate 80-HSA complex with self-
assembling clusters of polysorbate 80 over the protein surface in form of micelles that were able 
to entrap Iro during formation of Iro-HSA-NPs. The optimized process has led to the production 
of the Iro-HSA-NPs with particle size less than 80 nm. Successful entrapment of drug in NPs 
was confirmed by DSC, FTIR and fluorescence spectroscopy. The response surface graph clearly 
explained the positive effect of two critical factors (Iro: HSA ratio and crosslinking temperature) 
on entrapment efficiency and drug loading properties of NPs. These factors can be tailored to 
obtain the bespoke NPS with tunable particle size and drug loading. Lyophilization of Iro-HSA-
NPs resulted in good stability till 12-month period. Thus, the prepared NPs of Iro seem 
promising drug delivery system due to their small particle size, high drug entrapment and drug 
loading capacity. These drug loaded Iro-HSA-NPs also release drug in controlled manner for 
prolonged period of time, which would enhance the bioavailability of the drug to target site. 
Further studies are in progress to establish their pharmacokinetics and pharmacodynamics to 
harness their therapeutic potential as a drug delivery system. 
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Fig. 1 Overlay of fluorescence spectra of free HSA and HSA in presence of irinotecan (Iro), 
Polysorbate 80 and Iro Polysorbate 80 combination at λex = 280 nm. 
 
 
 
 
 
 
 
 
 
 Fig. 2 Schematic diagram for the preparation of Iro-HSA-NPs. 
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Fig. 3 Effect of polysorbate 80 concentration on (a) particle size and polydispersity index of Iro-HSA-NPs (b) % entrapment efficiency and % drug 
loading of Iro-HSA-NPs; Effect of (c) Ethanol concentration and (d) Iro: HSA ratioon particle size and polydispersity index of Iro-HSA-NPs; 
Influence of (e) Iro: HSA ratio and (f) Crosslinking temperatureon % entrapment efficiency and % drug loading of Iro-HSA-NPs.
(d) 
 (c) 
(f) (e) 
(a) (b) 
  
                            
Fig. 4 Response surface plot for the effect of Iro:HSA ratio and crosslinking temperature on (a) particle size (b) polydispersity index (c) % 
entrapment efficiency and (d) % drug loading of Iro-HSA-NPs. 
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Fig. 5 Overlay counter plot of responses for design space for Iro-HSA-NPs (a) Particle size < 80nm, polydispersity index <0.4, entrapment efficiency 
>70% and drug loading > 7% (b) Particle size <75nm, polydispersity index <0.4, entrapment efficiency >70% and drug loading >7% (c) Particle size 
<80nm, polydispersity index <0.3, entrapment efficiency >70% and drug loading >7% (d) Particle size <80nm, polydispersity index <0.4, entrapment 
efficiency >75% and drug loading >7% (e) Particle size <80nm, polydispersity index<0.4, entrapment efficiency >70% and drug loading >8% (f) 
Particle size <80nm, polydispersity index <0.4, entrapment efficiency >75% and drug loading >9%. 
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Fig. 6 (a) Surface electron microscopy images of lyophilized Iro-HSA-NPs and (b) after 
reconstitution of  lyophilized NPs (c) DSC thermogram overlay of irinotecan (Iro), Human 
serum albumin (HSA) and Irinotecan HSA Nanoparticles (Iro-HSA-NPs), (d) FTIR spectra 
of HSA, Irinotecan and Iro-HSA-NPs, (e) Flouoroscence spectroscopy of Blank and Iro-
HSA-NPs and (f) In-vitro release of irinotecan from Iro-HSA-NPs in phosphate buffer 
saline pH 7.4 (PBS 7.4) and Phospahte buffer pH 5 (PB 5)  at 370 C; Inset In-vitro release of 
irinotecan from Iro-HSA-NPs in phosphate buffer saline pH 7.4 (PBS 7.4) and Phospahte 
buffer pH 5 (PB 5)  at 370 C till 8 hours. 
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Fig. 7 Short-term stability study of Iro-HSA-NP dispersion; Effect on (a) mean particle 
size (b) polydispersity index and (c) zeta potential (mV) recorded over a period of 96 
hours storage at 40C(  ) and 250C (   ). 
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Fig. 8 Long-term stability of freeze dried  Iro-HSA-NPs; Effect on (a) Mean particle size (b) 
Polydispersity index (c) Zeta potential and (d) Entrapment efficiency recorded over period 
of 24 months storage at 40C.  The freeze dried samples were reconstituted before analysis. 
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Table 1: Mean particle size and polydispersity index of Iro-HSA-NPsat different 
homogenization pressures and number of homogenization cycles 
MPS-Mean particle size; PDI-Polydispersity index 
Table 2: Input variables and their levels for design of experiments 
       Iro:Irinotecan; HSA: human serum albumin 
Homogeniz
ation 
Pressure 
Homogenization Cycles 
 2 4 6 8 
 MPS PDI MPS PDI MPS PDI MPS PDI 
200 853.3 0.984 500 0.675 350.4 0.582 302.4 0.441 
400 231.8 0.321 211 0.432 142.7 0.403 109.3 0.339 
600 100.5 0.321 94.9 0.346 81.9 0.21 78.84 0.186 
800 105.2 0.491 98.1 0.473 Aggre
gation 
Aggre
gation 
Aggre
gation 
Aggreg
ation 
 Levels 
Input variables -1 0 +1 
X1=Iro: HSA ratio 1:10 1:20 1:30 
X2 = Crosslinking Temperature (0C) 50 55 60 
Response : Particle size (Y1), Polydispersity Index (Y2), % Entrapment Efficiency (Y3) 
and %  Drug Loading (Y4) 
 46 
 
 
Table 3: Statastical analysis results of ANOVA 
 
Table 4: Selection and optimization of cryoprotectant for freeze-drying 
 Type of Cryoprotectant 
 Mannitol Trehalose 
Cryoprotectant 
(% w/v) 
Particle 
size (nm) 
PDI Particle 
size (nm) 
PDI 
0 105.2 0.590 109.8 0.601 
2 90.2 0.342 62.8 0.419 
4 91.7 0.310 80.4 0.216 
6 72.0 0.290 89.0 0.301 
 
 
 Particle Size PDI % EE % DL 
Coefficient p 
value 
Coefficient p 
value 
Coefficient p  
value 
Coefficient p 
value 
Constant 71.55  0.19  60.00  5.78  
X1 0.097 0.8362 0.045 0.1789 9.96 < 
0.0001 
2.79 0.0001 
X2 1.33 0.0386 0.071 0.05 7.43 < 
0.0001 
0.87 0.050 
X1X2 -2.28 0.132 -0.031 0.5664 -0.86 0.0950 0.009 0.9835 
X12 3.22 0.010 0.14 0.0232 1.27 0.0520 -0.36 0.5777 
X22 6.66 0.0007 -0.065 0.3750 0.56 0.3654 0.95 0.1855 
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1 Ishikawa diagram illustrating product and process variables influencing the critical 
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Fig.S2:Binding study of irinotecan and HSA by fluorescence quenching method (a) 
Fluorescence Spectra (top to bottom) of (a) HSA and (b-f) HSA in the presence of irinotecan 
in concentration range of 20 µg-400 µg/ml (b) Stern-Volmer plot of F0/F versus Iro for HSA 
in the presence of different Iro concentration (20-400µg/ml) (c) Binding plot of log (F0-F)/F 
versus log Iro conc. (20-400µg/ml). 
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(c)  
 
 
Fig. S3: Predicted vs actual response plot (a) Particle size (b) Polydispersity Index (c) % 
Entrapment efficiency (d) % Drug Loading 
 
 
(a) 
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Fig. S4: (a) Particle size distribution of Iro-HSA-NPsby dynamic light scattering 
spectroscopy (b) Zeta potential of Iro-HSA- 
Table S1: Risk assessment matrix for control of critical quality attributes for fabricating Iro-
HSA-NPs 
(b) 
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Risk assessment related to Particle Size 
Polydispersit
y Index 
Entrapmen
t Efficiency 
Drug 
Loadin
g 
Stabilit
y 
Materials 
Iro: HSA 
Ratio 
Mediu
m Medium High High Low 
Polysorbate 
80 
Mediu
m Medium High High High 
Ethanol High High Low Low Medium 
Process 
IroHSA 
incubation 
time 
Low Low High High Medium 
Rate of 
ethanol 
addition 
High High Low Low Low 
Crosslinking 
temperature High High High High Low 
Stirring speed High High Low Low Medium 
Homogenizatio
n 
Temperature High High High High Low 
Pressure High High Low Low High 
Cycle Medium Medium Medium Medium Medium 
Freeze Drying Cryoprotectant High High Low Low High 
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Table S2: Optimization of incubaton time of Irinotecan and human serum albumin solution 
for preparation of Iro-HSA-NPs 
 
 
 
 
 
Incubation time (hours) Appearance of Iro HSA solution 
No incubation  Unclear solution with drug precipitates 
1     Unclear solution with drug precipitates  
2 Hazy solution with no precipitates 
3 Clear solution 
